Literature DB >> 24170029

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.

K Mayer1, G H Gielen2, W Willinek3, M C Müller4, D Wolf1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24170029     DOI： 10.1038/leu.2013.320

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Severe peripheral arterial disease during nilotinib therapy.

Authors:  Philipp Le Coutre; Delphine Rea; Elisabetta Abruzzese; Hervé Dombret; Malgorzata M Trawinska; Susanne Herndlhofer; Bernd Dörken; Peter Valent
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

3.  Nilotinib-associated vascular events.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-24

4.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

5.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

Authors:  T D Kim; D Rea; M Schwarz; P Grille; F E Nicolini; G Rosti; L Levato; F J Giles; H Dombret; T Mirault; H Labussière; R Lindhorst; W Haverkamp; I Buschmann; B Dörken; P D le Coutre
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528

Review 6.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

7.  Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

Authors:  F J Giles; M J Mauro; F Hong; C-E Ortmann; C McNeill; R C Woodman; A Hochhaus; P D le Coutre; G Saglio
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528
  7 in total
  14 in total

Review 1.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 2.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

Review 3.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

Review 4.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

5.  Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Authors:  Preetesh Jain; Hagop Kantarjian; Prajwal C Boddu; Graciela M Nogueras-González; Srdan Verstovsek; Guillermo Garcia-Manero; Gautam Borthakur; Koji Sasaki; Tapan M Kadia; Princy Sam; Hycienth Ahaneku; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Jorge E Cortes
Journal:  Blood Adv       Date:  2019-03-26

Review 6.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

7.  Nilotinib as a risk factor for ischaemic stroke: A series of three cases.

Authors:  J B Gómez-Galván; S Borrego; N Tovar; L Llull
Journal:  Neurologia       Date:  2016-01-06       Impact factor: 3.109

Review 8.  Targeted Therapy for Medullary Thyroid Cancer: A Review.

Authors:  S R Priya; Chandra Shekhar Dravid; Raghunadharao Digumarti; Mitali Dandekar
Journal:  Front Oncol       Date:  2017-10-06       Impact factor: 6.244

9.  Arterial hypertension assessment in a population with chronic myeloid leukemia.

Authors:  Ricardo Roa-Chamorro; Fernando Jaén-Águila; José Manuel Puerta-Puerta; Lucía Torres-Quintero; Pablo González-Bustos; Juan Diego Mediavilla-García
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

10.  Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors:  Zhe Wang; Xiaoyu Wang; Zhen Wang; Yuyi Feng; Yaqin Jia; Lili Jiang; Yangliu Xia; Jun Cao; Yong Liu
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.